BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II (World)
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/23/2014
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Positive Top-Line Data From U.S. Phase 2a Trial With Oral Insulin In Type 1 Diabetes 10/22/2014
Nuvo Research Inc. (NRI.TO) Completes WF10™ U.S. Market Study For Treatment Of Refractory Allergies 10/22/2014
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Designation From European Medicines Agency For The Treatment Of Dravet Syndrome 10/22/2014
Maxwell Biotech Portfolio Company Hepatera Announces Proof-Of-Concept Clinical Results With Myrcludex B, A Novel Entry Inhibitor For Treatment Of Chronic Hepatitis B And Delta 10/21/2014
TWi Biotechnology Receives Orphan Drug Designation For Its Lead Drug Candidate AC-201 In United States 10/21/2014
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Cannabis Biopharma GW Pharmaceuticals Sees Disappointing Data For Colitis Drug 10/15/2014
Tekmira (TKMR)'s Partner Reports Positive Clinical Data For LNP-Enabled Patisiran 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014
Biotron Limited (BIT:AU) Release: BIT225 Trial Results Show Effective Cure Of Hepatitis C 10/10/2014
Galapagos NV (GLPG.BR) Presents Novel Cystic Fibrosis Combination Therapy At NACFC 10/9/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy 10/8/2014
Medgenics, Inc. To Present Initial Clinical Data From MDGN-201 Study At European Society Of Gene And Cell Therapy Congress 10/7/2014
Foamix Pharmaceuticals, Ltd. (FOMX) Announces Initiation Of Phase 2 Trial With FDX104 In Chemotherapy Induced Rash 10/6/2014
Collaboration With Dr. Stephen Waxman Of Yale University To Evaluate Pharmacology Of Nav1.7 Mutations In Chronic Pain Disorders 10/6/2014
Horizon Pharma plc.  (HZNP) Receives Orphan-Drug Designation For ACTIMMUNE(R) (Interferon gamma-1b) In Friedreich's Ataxia 10/6/2014
Galderma Initiates U.S. Study Of Novel Muscle Relaxant For Aesthetic Dermatology And Cosmetic Surgery 10/6/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer 9/30/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN)'s Dupilumab Successful In Phase 2 Study 9/30/2014
Bionomics Limited (BNO.AX) Presents BNC105 Phase 2 Renal Cancer Trial Biomarker Data 9/29/2014
Viralytics Ltd (VLA.AX) Release: Updated Positive Data From Phase 2 Trial Of CAVATAK In Late-Stage Melanoma 9/29/2014
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014
BioBlast Pharma (ORPN) Announces Initiation Of Its Canadian OPMD Clinical Study Center At McGill University, Montreal 9/22/2014
ProSensa Holding N.V. (RNA) Announces Commencement Of Re-Dosing Of Drisapersen In North America In Patients With Duchenne Muscular Dystrophy 9/18/2014
Immune Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial In Ulcerative Colitis 9/18/2014
Galapagos NV (GLPG.BR) Reports High Participation Rate In Long Term Extension Study With GLPG0634 In RA Patients 9/18/2014
BioBlast Pharma (ORPN) Announces Preclinical And Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study In OPMD 9/17/2014
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows Positive Data In A Proof Of Concept Study 9/17/2014
Amarantus BioSciences, Inc. Provides Program Update On Phase 2b Eltoprazine For Parkinson's Disease And Adult ADHD 9/17/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis 9/16/2014
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014
Prosonix Confirms The Potential Of Its Multi-Component Particle™ Technology For Developing Novel Inhaled Dual And Triple Combination Therapies For Respiratory Diseases 9/11/2014
Amarantus BioSciences, Inc. Announces Positive MANF Ocular Toxicology Data 9/9/2014
AstraZeneca PLC (AZN)’s Phase 2 Lung Drug Data Gives Mixed Messages 9/9/2014
ProSensa Holding N.V. (RNA) Announces Lancet Neurology Publication Of An Exploratory Phase 2 Study (DEMAND II) Demonstrating Efficacy And Safety Of Drisapersen In Patients With Duchenne Muscular Dystrophy 9/8/2014
European Medicines Agency Accepts TiGenix Pediatric Investigation Plan For Cx601 9/8/2014
Kamada Ltd. (KMDA) Reports Final Results From Phase 2/3 Clinical Trial Of Inhaled Alpha-1 Antitrypsin To Treat Alpha-1 Antitrypsin Deficiency 9/4/2014
Oncolytics Biotech Inc. (ONC.TO) Neuroderm Announces Start Of Phase 2a Study Of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration For Patients With Severe Parkinson's Disease 9/3/2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis 9/3/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Adolescents With ADHD 9/2/2014
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer (PFE) Bid; Start Of New Cancer Trial 9/2/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Pharma Two B Ltd. Expands List Of Clinical Sites Enrolling For Phase IIb Study Of P2B001 For PD To 25 7/2/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Neurim Pharmaceuticals Announces Publication Of Positive Effects Of Add-On Circadin® In Alzheimer's Disease Patients 6/19/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014
ALK-Abello A/S’s Partner For Japan Announces Trial Results For House Dust Mite SLIT-Tablet 6/16/2014
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014
Umecrine Mood's Premenstrual Dysphoric Disorder (PMDD) Drug Fails Phase 2 Study 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans 6/9/2014
PsiOxus Therapeutics Limited Announces Positive Study Results Of Oncolytic Vaccine Enadenotucirev At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Jazz Pharmaceuticals plc (JAZZ) Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 6/3/2014
Novartis AG (NVS)'s Drug Zykadia™ Shrank Tumors In Phase 1 Study 6/3/2014
Can-Fite BioPharma (CFBI) Announces That The FDA Has Agreed With Its Phase 2 Liver Cancer Protocol 6/2/2014
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014
D-Pharm Ltd. Reports Completion Of The Second Dose Tier In Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 6/2/2014
BioTie Therapies Corp.: Nepicastat Study In Cocaine Dependence Completes Enrollment Ahead Of Schedule - Top-Line Data Expected Around End 2014 5/27/2014
TRANSGENE (ENX:TNG) Announces Promising Results In An Update From The Phase 2b Part Of TIME Trial With TG4010 In Advanced Non-Small Cell Lung Cancer 5/27/2014
Edison Pharmaceuticals, Inc.'s EPI-743 Granted Orphan Designation For Leigh Syndrome In Japan 5/21/2014
MediWound (MDWD) Initiates Second Phase 2 Clinical Trial Of Escharex™ To Treat Chronic And Other Hard-To-Heal Wounds 5/21/2014
MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL 5/20/2014
Sanofi Pasteur (SASY.PA) Announces Favorable Phase 2 Study Results For Investigational Clostridium difficile Vaccine At The American Society for Microbiology Meeting 5/19/2014
Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure 5/19/2014
Pluristem Therapeutics (PSTI) Receives Clearance From South Korea To Use PLX Cells Manufactured At Its New Facility In Its Advances Studies 5/19/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
Telormedix' Vesimune Successfully Completes Phase 2 For Carcinoma In Situ Of The Bladder 5/16/2014
AstraZeneca PLC (AZN) Touts Success In 2 Phase 2 Studies 5/15/2014
AstraZeneca PLC (AZN) Announces Results Of Phase 2b Studies 5/13/2014
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014
Alcobra (ADHD) Announces FDA Clearance Of Protocol For Phase 2b Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 5/8/2014
Biota Pharmaceuticals, Inc. Provides An Update On The Development Of Laninamivir Octanoate 5/1/2014
Can-Fite BioPharma (CFBI) Submits Protocol To FDA For Phase II Liver Cancer Study 4/29/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Prima Biomed (PRR.AX)'s CAN-004 Phase 2 Trial For Cvac™ Commences Recruitment 4/28/2014
FDA Approves Commencement Of BrainStorm Cell Therapeutics Inc.'s Phase 2 ALS Clinical Trial In U.S. 4/28/2014
Kamada Ltd. (KMDA.TA) Announces Significantly Improved Infusion Rate For Glassia® 4/24/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Pride-HD Study Enrolling Patients Globally To Further Evaluate Pridopidine For The Symptomatic Treatment Of Huntington’s Disease 4/24/2014
Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT 4/23/2014
Galapagos NV (GLPG.BR) Release: GSK2586184 Met Primary Endpoint In Phase 2a Psoriasis Study 4/17/2014
Final Data From The Phase 2 COSMOS Study Of Janssen Research & Development's Once-Daily Simeprevir In Combination With Sofosbuvir Presented At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 4/14/2014
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study 4/14/2014
GenKyoTex S.A. 's GKT137831 Found To Reverse Fibrosis And Improve Survival In A Model Of Persistent Lung Fibrosis 4/10/2014
Gilead Sciences, Inc. (GILD) Announces Phase 2 Results For Two Investigational All-Oral Sofosbuvir-Based Regimens For The Treatment Of Chronic Hepatitis C 4/10/2014
BioLineRx Ltd. Announces Investigator-Initiated Study For Novel Chronic Myeloid Leukemia Treatment 4/10/2014
Alcobra (ADHD) Submits Protocol To FDA For Phase 2b Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 4/10/2014
Adocia Reports Positive Results From Phase 2a Clinical Study Of Ultra-Fast Acting Biochaperone® Lispro 4/9/2014
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014
Mologen AG (MOLGF.PK): DSLIM® Shows Superior Immunoactivation Capabilities 4/8/2014
Viralytics Ltd (VLA.AX) Release: Positive Interim Phase 2 Trial Results For CAVATAK™, Novel Cancer Immunotherapy 4/8/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Alnylam Pharmaceuticals (ALNY) Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-Ttrsc, A Subcutaneously Delivered Rnai Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR) 4/2/2014
PRANA Biotechnology (PRAN) Tanks As Lead Drug Fails Alzheimer's Study 4/1/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Tout Positive Phase 2b Bipolar Depression Data 3/31/2014
Published Analysis Confirms Positive Results From Auris Medical AG's Phase 2b Study With AM-101 In Treatment Of Acute Inner Ear Tinnitus 3/31/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Shows Off Positive Phase 2b Data For Cariprazine To Treat Depression 3/21/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Recruitment Completed 3/21/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test 3/19/2014
Ipsen (IPN.PA): Dysport Incontinence Treatment Phase 2a Trial Positive 3/18/2014
Pharma Two B Ltd. Commences Phase 2b Study Of Fixed Dose Combination Therapy “P2B001” For Parkinson’s Disease 3/18/2014
Asthma Leader GlaxoSmithKline (GSK) Faces Competition From Roche (RHHBY), AstraZeneca PLC (AZN), Sanofi (France) (SAN.PA), And Teva Pharmaceutical Industries Limited (TEVA) 3/18/2014
Can-Fite BioPharma (CFBI): Phase II Study Protocol To Treat Patients With Advanced Liver Cancer With CF102 Has Been Approved By The IRB In Israel 3/17/2014
Neovacs SA Announces Positive IDSMB Review Of The Phase 2b Study Of TNF-Kinoid In Rheumatoid Arthritis 3/12/2014
ALK-Abello A/S’s Partner For Japan Reports Positive Trial Results For House Dust Mite SLIT-Tablet 3/10/2014
Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co., Ltd. In Japan 3/10/2014
Roche (RHHBY) Drug Cuts Asthma Attacks, Improves Lung Function In Phase 2b Study 3/6/2014
Medivir AB (MVRBF) Release: SVR12 Results From A Phase 2a Study Evaluating Simeprevir And Daclatasvir In Hepatitis C Patients Of Genotype 1 Have Been Presented 3/5/2014
Galapagos NV (GLPG.BR), GlaxoSmithKline (GSK) Anti-Inflammatory Drug Pact Hits A Roadblock 3/4/2014
D-Pharm Ltd. Reports The Successful Interim Analysis Of Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 3/4/2014
Kamada Ltd. (KMDA.TA) Completes Enrollment In U.S. Pivotal Clinical Trial With Kamrab As A Post-Exposure Treatment For Rabies 3/4/2014
Genticel Reaches An Important Milestone By Launching Its Phase II Trial In Women Infected With High-Risk HPV Before The Appearance Of High Grade Cervical Lesions 3/4/2014
Atopix Shows Off Positive Phase 2b Results For Once Daily OC459 In Asthma 3/3/2014
Novartis AG (NVS)'s Experimental Skin Cancer Drug Meets Primary Endpoint In Pivotal Phase 2 Trial 2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014) 2/19/2014
Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis 2/18/2014
Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis 2/17/2014
Ario Pharma Commences Phase 2a Trial Of TRPV1 Inhibitor For Cough Associated With Chronic Obstructive Pulmonary Disease 2/11/2014
Oramed Pharmaceuticals Inc. (ORMP) Submits Phase 2a Protocol To FDA For The Treatment Of Type 1 Diabetes With Its Oral Insulin Capsule 2/10/2014
AstraZeneca PLC (AZN) Takes On Merck & Co., Inc. (MRK) In Alzheimer's Drug Race 2/7/2014
Can-Fite BioPharma (CFBI) Submitted Phase II Study Protocol With CF102 To Treat Patients With Advanced Liver Cancer 2/6/2014
Targovax TG01 Immunotherapy Reaches Phase 2a In Operable Pancreatic Cancer 2/6/2014
Spinifex Pharmaceuticals ' Phase 2 Results Published In The Lancet Show EMA401 To Be Effective In Reducing Pain In Postherpetic Neuralgia 2/5/2014
Oramed Pharmaceuticals Inc. (ORMP) Announces Successful FDA Phase 2a Clinical Trial Results 1/30/2014
Galapagos NV (GLPG.BR) Release: First Clinical Centers Opened For Phase 2 Crohn's Study With GLPG0634 1/30/2014
Positive Spinal Disc Repair Trial Results Using Mesoblast Limited (MSB.AX) Adult Stem Cells 1/30/2014
Allergy Therapeutics plc: Short Course Immunotherapy Effective In Reducing Ragweed Pollen Allergy 1/27/2014
Prosonix Reports Positive Top-Line Results From Its Phase 2 Clinical Study With PSX1002 In Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) 1/23/2014
BioLineRx Ltd. Receives Orphan Drug Designation For Novel Stem Cell Mobilization Treatment 1/23/2014
D-Pharm Ltd. Completes Recruitment Of Patients Into The First Dosage Tier Of Its Phase 2 Study With THR-18 In Acute Stroke Patients Treated With tPA. 1/21/2014
Prima Biomed (PRR.AX) Revised CAN-004 Trial Of Cvact In Ovarian Cancer Approved In Belgium - First Regulator To Approve Amended CVact Clinical Trial Design 1/20/2014
ERYtech Pharma Announces Clinical Trial Authorizations In Finland And Spain For Its European Phase 2b Study In AML 1/15/2014
D-Pharm Ltd. Announces Recruitment Of The First Patient Into Its Phase 2 Clinical Trial With DP-B99 In Acute High-Risk Pancreatitis 1/14/2014
GlaxoSmithKline (GSK)'s Tafinlar Drug Gets FDA Breakthrough Therapy Designation 1/14/2014
Apogenix' APG101 Demonstrates Significant Prolongation Of Overall Survival In Biomarker-Positive Patients In Phase II Trial For The Treatment Of Recurrent Glioblastoma 1/13/2014
Medivir AB (MVRBF) Release: Interim Results (SVR4) From A Phase 2 All-Oral Combination Study Of Simeprevir And Samatasvir (IDX719) For The Treatment Of Hepatitis C 1/13/2014
EntreMed, Inc. (ENMD) Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA 1/13/2014
Dezima Pharma Completes Patient Enrollment For TULIP Phase 2B Study With CETP Inhibitor TA-8995 1/13/2014
TRANSGENE (ENX:TNG) Announces Topline Preliminary Results From Phase 2b Part Of TIME Trial With TG4010 In Non-Small Cell Lung Cancer 1/9/2014
Positive Feedback From The Scientific Community For Anaconda Pharma's Phase 2a Data For AP611074 First Clinical Proof Of Concept For The Curative Treatment Of Condyloma 1/9/2014
Viralytics Ltd (VLA.AX) Release: Target Enrollment Achieved In CAVATAK™ USA Phase 2 Melanoma Trial With Excellent Interim Results 1/8/2014
Adocia Launches Phase 2a Clinical Trial For Its Ultra-Fast Acting Formulation Of Analog Insulin 1/6/2014
D-Pharm Ltd. Reports Enrollment Of First Patient Into Phase 2 Study Of THR-18 In Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 1/2/2014
Cerenis Therapeutics, Inc.'s Cholesterol Drug CER-001 Fails In Mid-Stage Trial 1/2/2014
Axelar AB's Phase 2 Lung Cancer Study Data Does Not Impress 12/31/2013
Antisense Therapeutics Limited (ANP.AX) Release: Positive Results Achieved From Interim Analysis Of ATL1103 Phase II Trial 12/23/2013
BioSpecifics Technologies Corporation (BSTC) Announces Top-Line Data From Phase 2 Trial Of CCH For Canine Lipoma 12/23/2013
Can-Fite BioPharma (CFBI) Soars On Positive Phase 2 Rheumatoid Arthritis Study; Stock Up +19.23% At Market Close (Dec. 23, 2013) 12/23/2013
GlaxoSmithKline (GSK)'s Malaria Drug Wins FDA "Breakthrough" Status 12/23/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Successful Results From Ex-US Pharmacokinetic Study Of Its Oral Insulin For The Treatment Of Type 1 Diabetes 12/20/2013
MicuRx Pharmaceuticals Expands Global Clinical Trial Program For Oral Antibiotic MRX-I 12/20/2013
Alcobra (ADHD) Release: FDA Grants Orphan Drug Status To Metadoxine In Fragile X Syndrome 12/19/2013